Autolus Therapeutics plc (AUTL) Stock

About Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Autolus Therapeutics plc is led by CEO Christian Martin Itin, employs 752 people, headquartered in London, GB, publicly traded since 2018.

the stock is valued at a negative price-to-earnings (P/E) ratio of -1.35, reflecting a net loss over the last twelve months. Over the past 52 weeks the stock has ranged between $1.18 and $2.70, and currently trades 45.9% below its 52-week high.

On profitability, Autolus Therapeutics plc generates a return on equity (ROE) of -161.80% (negative, reflecting a net loss), return on capital employed of -52.52%, an operating margin of -361.33%, a net profit margin of -384.00%.

Official website: www.autolus.com

Autolus Therapeutics plc by the numbers, 2021–2025

Compounded, revenue has grown —% a year over five years, —% over three, 650.0% over the last twelve months. Net profit fell to $-288.0M.

The most recent net margin is -384.00%. On a trailing twelve-month basis to Mar '26, revenue is $77.0M and net profit $-269.0M.

Cash from operations was $-284.0M in the latest year, positive in 0 of the last 5.

Return on equity has averaged -103.0% over five years, and was -259.5% in the most recent year.

The share price itself has compounded at —% a year over five years, -16.4% over three, -40.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Autolus Therapeutics plc (AUTL) — frequently asked questions